The PI3/AKT/mTOR/RPS6 pathway confers resistance in HER2-Amplified Gastric Cancer through the stimulation of the nuclear factor erythroid 2-related factor 2 (NRF2), a factor involved in chemo- and radioresistance in different tumors [121]. Here, RPS6 is linked to gastric cancer.